Biochemical markers and skeletal metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2919-2926

  Demers, Laurence M ^a,c   Costa, Luis ^b   Lipton, Allan ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bone markers; Bone metastases; Bone specific alkaline phosphatase; N telopeptide

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; PYRIDINOLINE; TUMOR MARKER; UNCLASSIFIED DRUG;

BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; PRIORITY JOURNAL; URINE LEVEL; VALIDATION PROCESS;

EID: 0034659963     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z     Document Type: Conference Paper

References (40)

1. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997;80(8 Suppl):1572-80.
2. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80(8 Suppl):1546-56.
3. Haeckel C, Ayala AG, Radig K, Raymond AK, Roessner A, Czerniak B. Protease expression in dedifferentiated parosteal osteosarcoma. Arch Pathol Lab Med 1999;123:213-21.
4. Clohisy DR, Palkert D, Ramnaraine ML, Pekurovsky I, Oursler MJ. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J Orthop Res 1996;14:396-402.
5. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998;78:157-69.
6. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? an evidence-based review. J Clin Oncol 1998;16:1218-25.
7. Demers LM, Costa L, Chincilli V, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41: 1489-94.
8. Houze P, Bellik B, Extra JM, Bouro F, Bousquet B. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin Chim Acta 1999;281:77-88.
9. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 1997;80:1760-7.
10. Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 1996;156:1691-5.
11. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996;73:1581-7.
12. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9.
13. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 1996;271:26508-16.
14. Robins SP, Duncan A, Wilson N, Evans BJ. Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clin Chem 1996;42:1621-6.
15. Kent GN. Standardization of marker assays - pyridinoline/ deoxypyridinoline. Scand J Clin Lab Invest Suppl 1997;227: 73-9.
16. Rosano TG, Peaston RT, Bone HG, Woitge HW, Francis RM, Seibel MJ. Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation. Clin Chem 1998;44:2126-32.
17. Hanson DA, Weis MA, Bollen AM. A specific immunoassay for monitoring human bone reposition: quantitation of Type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
18. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-63.
19. Demers LM, Heerkoper M. Recent advances in biochemical markers of bone turnover. Clin Chem 1994;40:1994-5.
20. Bettica P, Masino M, Cucinotta E, Vago T, Norbiato G, Moro L, et al. Comparison of the clinical performance of the immunoenzymometric assays for N-terminal and C-terminal type I collagen telopeptides and the HPLC assay for pyridinium cross-links. Eur J Clin Chem Clin Biochem 1997; 35:63-8.
21. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps One Step ELISA: first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-9.
22. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995;71: 1061-4.
23. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Ogata E. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 1999;24:15-20.
24. Overgaard K, Alexandersen P, Riis BJ, Christiansen C. Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. Clin Chem 1996;42:973-4.
25. Price CP, Milligan TP, Darte C. Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum. Clin Chem 1997; 43:2052-7.
26. Magnusson P, Larsson L, Englund G, Larsson B, Strang P, Selin-Sjogren L. Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem 1998;44:1621-8.
27. Suvanto-Luukkonen E, Risteli L, Sundstrom H, Penttinen J, Kauppila A, Riseli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chem Acta 1997;266:105-16.
28. Jukkola A, Tahtela R, Tholix E, Vuorinen K, Blanco G, Risteli L, et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 1997;57:5517-20.
29. Withold W, Friedrich W, Reinauer H. Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases. Ann Clin Biochem 1996;33:421-7.
30. Coleman RE, Rubens, RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
31. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80:1668-73.
32. Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, et al. Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 1999;85:1951-7.
33. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997;157:539-43.
34. Blomquist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9.
35. Costa L, Demers LM, Speicher T, Gouveia, T, Curley E, Harvey H, et al. Biochemical markers of bone turnover correlate with the extent of metastatic bone disease. American Society of Clinical Oncology, May 1999.
36. Demers LM. Biochemical markers in the management of patients with metastatic bone disease. Clin Chem 1999,45: 1131-2.
37. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999;45:1240-7.
38. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18, Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17:846-54.
39. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19, Aredia Breast Cancer Study Group. J Clin Oncol 1998,16:2038-44.
40. Costa L, Demers LM, Gouveia A, Schaller J, Costa EB, DeMoura MC, Lipton A. Correlation of urinary N-telopeptide levels with progression of bone metastases: a prospective study [Abstract 12]. Cancer 2000;88(Suppl):3094.